Difference between revisions of "Electroconvulsive therapy"

From WikiAnesthesia
VisualWikitext
(Formatting change)
(Format change)
Line 8: Line 8:
| considerations_intraoperative =  
| considerations_intraoperative =  
| considerations_postoperative =  
| considerations_postoperative =  
}}
}}Electroconvulsive therapy (ECT) is a medically induced generalized seizure that consists of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.<ref name=":0">{{Cite book|last=Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller.|first=|title=Faust's Anesthesiology Review|publisher=|year=2015|isbn=|location=Print|pages=Anesthesia for Electroconvulsive Therapy; 490-492}}</ref><ref name=":1">{{Cite book|last=Pardo, Manuel, Ronald D Miller|first=|title=Basics of Anesthesia 7th Edition|publisher=|year=2017|isbn=0323401155|location=Print|pages=669-671}}</ref> It is used for refractory depression (unipolar and bipolar types), depression with psychotic features, schizophrenia, and catatonia.<ref name=":1" /><ref name=":2">{{Cite web|last=ACCRAC|date=2019-03-13|title=Episode 112: Anesthesia for ECT with Christina Miller|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/|access-date=2021-08-22|website=ACCRAC Podcast|language=en}}</ref>


* <u>Background</u>:<ref name=":0">{{Cite book|last=Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller.|first=|title=Faust's Anesthesiology Review|publisher=|year=2015|isbn=|location=Print|pages=Anesthesia for Electroconvulsive Therapy; 490-492}}</ref><ref name=":1">{{Cite book|last=Pardo, Manuel, Ronald D Miller|first=|title=Basics of Anesthesia 7th Edition|publisher=|year=2017|isbn=0323401155|location=Print|pages=669-671}}</ref>
ECT is monitored by EEG, with electrodes placed in left unilateral, right unilateral (most common, fewer memory side effects), and bifrontal. Goal seizure duration is 30-60 seconds. For seizures lasting longer than 120 seconds, termination can be achieved with midazolam/propofol. The initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure. Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression, with total number of ECT sessions determined by patient's clinical response. Repeated rounds of ECT have been shown to increase seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered).
** Seizures induced by ECT are generalized seizures that consist of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.
 
** Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. If seizure > 120s consider termination with midazolam/propofol.
Mortality risk is extremely low, at <1 in 75,000 treatments.<ref name=":0" /> Most common adverse events include transient arrhythmias (10%–40%), gastric aspiration (2.5%), and MSK disorders (0.4%) including fractures. Additional adverse events include pulmonary edema, headache, memory disturbance, and agitation. Very rarely Takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.
** Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure.
 
** Configuration of electrode placement: Left unilateral, Right unilateral (most common, fewer memory side effects), & Bifrontal
Absolute contraindications include
** Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression. Total # of treatments determined by Pt’s clinical response.
** Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)
*<u>Morbidity and Mortality Rates</u>:<ref name=":0" />
** Mortality risk <1 in 75,000 treatments.
** Most common adverse events: Transient arrhythmias (10%–40%), gastric aspiration (2.5%), & MSK disorders (0.4%), including fractures.
** Additional adverse events: Pulmonary edema, HA, memory disturbance, & agitation. Very rarely takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.
*<u>Indications</u>:<ref name=":1" /><ref name=":2">{{Cite web|last=ACCRAC|date=2019-03-13|title=Episode 112: Anesthesia for ECT with Christina Miller|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/|access-date=2021-08-22|website=ACCRAC Podcast|language=en}}</ref>
** Refractory Depression (unipolar and bipolar types), Depression with Psychotic features, Catatonia, and schizophrenia
*<u>ABSOLUTE Contraindications</u>:<ref name=":0" /><ref name=":2" />
*<u>ABSOLUTE Contraindications</u>:<ref name=":0" /><ref name=":2" />
** Untreated Pheochromocytoma
** Untreated Pheochromocytoma
Line 34: Line 26:
** Severe osteoporosis (fracture risk)
** Severe osteoporosis (fracture risk)
** Thrombophlebitis
** Thrombophlebitis
*<u>Physiologic Changes</u>:<ref name=":0" /><ref name=":2" />
*<u>Pre-Induction Considerations:  <ref name=":0" /><ref name=":1" /><ref name=":2" /></u>
*<u>General Procedural Steps</u>:  <ref name=":1" /><ref name=":2" />
*<u>General Procedural Steps</u>:  <ref name=":1" /><ref name=":2" />
*# Pre-oxygenate well prior to induction
*# Pre-oxygenate well prior to induction
Line 81: Line 71:
=== Operating room setup<!-- Describe any unique aspects of operating room preparation. Avoid excessively granular information. Use drug classes instead of specific drugs when appropriate. If none, this section may be removed. --> ===
=== Operating room setup<!-- Describe any unique aspects of operating room preparation. Avoid excessively granular information. Use drug classes instead of specific drugs when appropriate. If none, this section may be removed. --> ===


=== Patient preparation and premedication<!-- Describe any unique considerations for patient preparation and premedication. If none, this section may be removed. --> ===
=== Patient preparation and premedication<!-- Describe any unique considerations for patient preparation and premedication. If none, this section may be removed. --><ref name=":0" /><ref name=":1" /><ref name=":2" /> ===


* ''Psychiatric Medication Management'':
* ''Psychiatric Medication Management'':
Line 129: Line 119:
Supine or with HOB elevated
Supine or with HOB elevated


=== Maintenance and surgical considerations<!-- Describe the important considerations and general approach to the maintenance of anesthesia, including potential complications. Be sure to include any steps to the surgical procedure that have anesthetic implications. --> ===
=== Maintenance and surgical considerations<!-- Describe the important considerations and general approach to the maintenance of anesthesia, including potential complications. Be sure to include any steps to the surgical procedure that have anesthetic implications. --><ref name=":0" /><ref name=":2" /> ===


* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
Line 190: Line 180:
|
|
|}
|}
== References ==
<references />
<references />
== References ==


[[Category:Surgical procedures]]
[[Category:Surgical procedures]]

Revision as of 09:24, 30 August 2021

Electroconvulsive therapy
Anesthesia type
Airway
Lines and access
Monitors
Primary anesthetic considerations
Preoperative
Intraoperative
Postoperative
Article quality
Editor rating
Comprehensive
User likes
0

Electroconvulsive therapy (ECT) is a medically induced generalized seizure that consists of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.[1][2] It is used for refractory depression (unipolar and bipolar types), depression with psychotic features, schizophrenia, and catatonia.[2][3]

ECT is monitored by EEG, with electrodes placed in left unilateral, right unilateral (most common, fewer memory side effects), and bifrontal. Goal seizure duration is 30-60 seconds. For seizures lasting longer than 120 seconds, termination can be achieved with midazolam/propofol. The initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure. Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression, with total number of ECT sessions determined by patient's clinical response. Repeated rounds of ECT have been shown to increase seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered).

Mortality risk is extremely low, at <1 in 75,000 treatments.[1] Most common adverse events include transient arrhythmias (10%–40%), gastric aspiration (2.5%), and MSK disorders (0.4%) including fractures. Additional adverse events include pulmonary edema, headache, memory disturbance, and agitation. Very rarely Takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.

Absolute contraindications include

  • ABSOLUTE Contraindications:[1][3]
    • Untreated Pheochromocytoma
    • Intracranial mass/↑ ICP
    • Recent MI or Stroke w/in last 30 days  
  • Relative Contraindications:[1]
    • Angina pectoris, CHF
    • COPD
    • Glaucoma, Retinal detachment
    • High-risk pregnancy
    • Severe osteoporosis (fracture risk)
    • Thrombophlebitis
  • General Procedural Steps: [2][3]
    1. Pre-oxygenate well prior to induction
    2. Once induction medications given & patient unconscious start mask ventilating & give paralytic
    3. Hyperventilate -> Hypocarbia (↓ seizure threshold)
    4. Bite guard placed prior to ECT initiation
    5. After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.


Preoperative management

Patient evaluation

System Considerations
Neurologic
Cardiovascular
Respiratory
Gastrointestinal
Hematologic
Renal
Endocrine
Other

Labs and studies

Operating room setup

Patient preparation and premedication[1][2][3]

  • Psychiatric Medication Management:
    • Can continue MAO inhibitors, TCAs, SSRIs, & antipsychotics w/ ECT
    • MAO Inhibitors: Avoid ephedrine (indirect-acting sympathomimetics cause exaggerated BP). Be aware they ↓ plasma cholinesterase activity → ↑ succinylcholine duration
    • Lithium – Risk for delayed awakening, memory loss, and postictal confusion. Hold for 12hr before ECT
    • Benzodiazepines – Hold for 12hr before ECT. May need to give flumazenil before ECT to have an adequate seizure duration.
  • Pacemaker vs Implantable Cardioverter-Defibrillator (ICD):
    • Pacemaker
      • If Not dependent on the device, a magnet should be available in event of device failure.
      • If Dependent on pacemaker, program device to asynchronous mode & a backup pacing mode should be available.
    • ICD:
      • Risk that the device misinterprets muscle movements as an abnormal cardiac rhythm and a discharge is possible.
      • Device should be deactivated & an external defibrillator should be immediately available with placement of external defibrillator pads strongly considered.
    • For a patient with an ICD & who is pacemaker dependent, the EP service should be consulted or in any other cases with pacing concerns.

Regional and neuraxial techniques

Intraoperative management

Monitoring and access

PIV x 1

Standard ASA monitors with 5 lead ECG. Single lead EEG

Induction and airway management

  • Induction:
    • Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold
    • Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability
    • Propofol: ↑ seizure threshold & ↓ seizure duration. Need higher stimulus voltages to achieve adequate seizure. May be useful in patients with history of long seizures.
    • Ketamine: can cause post-ECT confusion.
    • Remifentanil 200-400 mcg as an adjunct to lower dose of methohexital needed; net ↓ Sz threshold. Monitor for ↓HR/↓BP & chest wall rigidity. If unable to ventilate or very small TV, consider succinylcholine.
    • Sevoflurane can be used for inhalational induction when no IV access possible.
  • Paralytic:
    1. Succinylcholine 1- 1.5 mg/kg, titrate to adequate paralysis
    2. Rocuronium - Low dose & only if patient has contraindication to succinylcholine (reverse with sugammadex)
  • Initial PARAsympathetic discharge:
    1. Glycopyrrolate 0.2mg to prevent bradycardia. Usually given prior to induction agents
  • Subsequent Sympathetic discharge:
    1. Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
    2. Hyperglycemia often seen in insulin dependent Pt -> BG Pre/Post
  • Post-ECT Delirium (or if flumazenil given pre-induction):
    1. Midazolam 1-2mg

Positioning

Supine or with HOB elevated

Maintenance and surgical considerations[1][3]

  • ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
  • Cardiovascular
    • 1st: Parasympathetic response may cause asystole, bradycardia, PVCs, hypotension, & ventricular escape rhythm.
      • If known profound parasympathetic response, can blunt w/ glycopyrrolate pre-induciton
    • 2nd: Sympathetic tone ↑ with seizure generation -> ↑ HR, PVCs, bigeminy, trigeminy, sinus tachycardia, ST segment changes (↑ myocardial O2 consumption) & severe HTN.
      • Often resolves quickly, but if Pt requires intervention consider nitroglycerin, esmolol, or labetalol
  • Respiratory: Parasympathetic discharge -> at risk for laryngospasm, bronchoconstriction/wheezing
  • Neuro: Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & ↑BP -> ↑ICP
  • Neuroendocrine: ↑ corticotropin, cortisol, & catecholamines.
    • Effects on glucose levels vary; consider Pre/Post glucose in insulin dependent patients.
  • GI: ↑ intragastric pressure
  • Eye: ↑ intraocular pressure

Emergence

Postoperative management

Disposition

Pain management

Potential complications

Procedure variants

Variant 1 Variant 2
Unique considerations
Position
Surgical time
EBL
Postoperative disposition
Pain management
Potential complications

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller. (2015). Faust's Anesthesiology Review. Print. pp. Anesthesia for Electroconvulsive Therapy, 490–492.CS1 maint: multiple names: authors list (link)
  2. ↑ 2.0 2.1 2.2 2.3 Pardo, Manuel, Ronald D Miller (2017). Basics of Anesthesia 7th Edition. Print. pp. 669–671. ISBN 0323401155.CS1 maint: multiple names: authors list (link)
  3. ↑ 3.0 3.1 3.2 3.3 3.4 ACCRAC (2019-03-13). "Episode 112: Anesthesia for ECT with Christina Miller". ACCRAC Podcast. Retrieved 2021-08-22.

Top contributors: Alexander Jaksic, Tony Wang and Chris Rishel

Retrieved from "https://wikianesthesia.org/w/index.php?title=Electroconvulsive_therapy&oldid=2818"